India has green-lighted molnupiravir for restricted emergency use in COVID-19, paving the way for the arrival of around a dozen generic versions of Merck & Co., Inc. and Ridgeback Biotherapeutics LP ‘s oral antiviral therapy in the country.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?